HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 22, No 06, June 2018 – Cancer - Therapies and strategies for better patient outcomes       » Gardasil 9 supply running short in Hong Kong       » China helps Tajikistan tackle grassland degradation       » Immuno-oncology trials in China surge more than 50 per cent       » Yeast for industrial biotechnology       » Uncontrolled hypertension in rural communities      
BIOBOARD - AUSTRALIA
Senz Oncology initiates VAL-1000 clinical trial in patients with acute leukemias
Senz Oncology Pty Ltd (Senz) has announced that the first patient has commenced treatment in a Phase I/II clinical evaluation of VAL-1000 in patients with acute leukemias (protocol SO-2012-1). 

The single-arm, open-label clinical trial will be conducted under the guidance of Principal Investigator, Dr. Andrew Wei, Head of Leukemia Services at The Alfred Hospital, Melbourne, Australia.

“We are very pleased to have Dr. Wei as Principal Investigator for the VAL-1000 Phase I/II clinical trial,” said Dr. Ian Nisbet, Executive Director, Senz Oncology. “Dr. Wei's input into the preclinical studies provided new scientific insights and the clinical rationale for VAL-1000 in acute leukaemias”.

The primary objective of the trial is to evaluate the safety and tolerability of VAL-1000 in adult patients with acute leukemias that are unsuitable for treatment with standard chemotherapy treatments. 

The trial will also evaluate secondary objectives including assessing patient related efficacy outcomes, measuring VAL-1000 pharmacokinetics and defining a dose level for testing in subsequent Phase II clinical trials. 

Approximately 900 patients are diagnosed with Acute Myeloid Leukemia (AML) in Australia annually. The majority will relapse, especially those over the age of 60 and with poor risk cytogenetic and molecular characteristics. Patients falling into these categories have very limited treatment options once standard approaches have been exhausted.

According to Dr. Anthony Filippis, Executive Director, Senz Oncology, “The trial will be the first time that VAL-1000 has been tested clinically for the treatment of acute leukaemias; if ultimately shown to be safe and efficacious it could provide a completely new treatment option for patients.”

Click here for the complete issue.

NEWS CRUNCH  
news Shire, Microsoft and EURORDIS form Global Commission to accelerate time to diagnosis for children with rare diseases
news EmTech Asia explores future of life, humanity and economy
news Biology of Ageing II - Impactful Interventions
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  
Click here to receive APBN e-newsletters once a month!

APBN Editorial Calendar 2018
January:
Obesity / Outlook for 2018
February:
Searching for the fountain of youth
March:
Women in Science - Making a difference
April:
Digestive health in the 21st century - Trust your guts
May:
Dental health - The root to good health
June:
Cancer - Therapies and strategies for better patient outcomes
July:
Water management / Vaccination
August:
Regenerative medicine / Biotech start ups
September:
Digital healthcare / 3D printing
October:
Bones / Breast cancer
November:
Liver health / Top science research nations & institutions
December:
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy